Generic name: plerixafor
Dosage form: injection
This dosage information does not include all the information needed to use Mozobil safely and effectively. See full prescribing information for Mozobil.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Recommended Dosage and Administration
Vials should be inspected visually for particulate matter and discoloration prior to administration and should not be used if there is particulate matter or if the solution is discolored.
Begin treatment with Mozobil after the patient has received G-CSF once daily for four days. [see Dosage and Administration (2.2)] Administer Mozobil approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days.
The recommended dose of Mozobil is 0.24 mg/kg body weight by subcutaneous (SC) injection. Use the patient’s actual body weight to calculate the volume of Mozobil to be administered. Each vial delivers 1.2 mL of 20 mg/mL solution, and the volume to be administered to patients should be calculated from the following equation:
0.012 X patient’s actual body weight (in kg) = volume to be administered (in mL)
In clinical studies, Mozobil dose has been calculated based on actual body weight in patients up to 175% of ideal body weight. Mozobil dose and treatment of patients weighing more than 175% of ideal body weight have not been investigated.
Based on increasing exposure with increasing body weight, the plerixafor dose should not exceed 40 mg/day. [see Clinical Pharmacology (12.3)]
Recommended Concomitant Medications
Administer daily morning doses of G-CSF 10 micrograms/kg for 4 days prior to the first evening dose of Mozobil and on each day prior to apheresis. [see Clinical Studies (14)]
Dosing in Renal Impairment
In patients with moderate and severe renal impairment (estimated creatinine clearance (CLCR) ≤ 50 mL/min), reduce the dose of Mozobil by one-third to 0.16 mg/kg as shown in Table 1. If CLCR is ≤ 50 mL/min the dose should not exceed 27 mg/day, as the mg/kg-based dosage results in increased plerixafor exposure with increasing body weight. [see Clinical Pharmacology (12.3)] Similar systemic exposure is predicted if the dose is reduced by one-third in patients with moderate and severe renal impairment compared with subjects with normal renal function. [see Clinical Pharmacology (12.3)]
| Estimated Creatinine Clearance
|> 50||0.24 mg/kg once daily (not to exceed 40 mg/day)|
|≤ 50||0.16 mg/kg once daily (not to exceed 27 mg/day)|
The following (Cockroft-Gault) formula may be used to estimate CLCR:
Creatinine clearance (mL/min) = weight (kg) X (140 – age in years)
72 X serum creatinine (mg/dL)
Creatinine clearance (mL/min) = 0.85 X value calculated for males
There is insufficient information to make dosage recommendations in patients on hemodialysis.